US · NTLA
Intellia Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Cambridge, MA 02139
- Website
- intelliatx.com
Price · as of 2025-12-31
$13.26
Market cap 1.6B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $19.99 | +50.75% |
| Intrinsic Value(DCF) | $6.97 | -47.44% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | $14.11 | $971.83 | $670,102.92 | $1.49 | $0.00 |
| 2017 | $34.95 | $133.15 | $5.94 | $0.00 | $0.00 |
| 2018 | $15.69 | $26.45 | $8.47 | $0.00 | $0.00 |
| 2019 | $14.52 | $24.91 | $6.28 | $0.00 | $0.00 |
| 2020 | $65.52 | $49.15 | $7.91 | $0.00 | $0.00 |
| 2021 | $61.29 | $37.15 | $9.37 | $0.00 | $124.70 |
| 2022 | $35.82 | $25.62 | $9.06 | $0.00 | $0.00 |
| 2023 | $29.97 | $26.49 | $4.78 | $0.00 | $113.55 |
| 2024 | $10.35 | $18.56 | $2.13 | $0.00 | $0.00 |
| 2025 | $15.44 | $19.99 | $1.29 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Intellia Therapeutics, Inc.'s (NTLA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $19.99
- Current price
- $13.26
- AI upside
- +50.75%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$6.97
-47.44% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| NTLA | Intellia Therapeutics, In… | $13.26 | 1.6B | +51% | -47% | — | — | -3.22 | 2.49 | 24.73 | -3.27 | — | 2.49 | 76.47% | -651.67% | -609.85% | -67.26% | -110.87% | -51.06% | 0.14 | — | 5.08 | 4.42 | 0.15 | -2743.00% | 1692.00% | 0.00% | -21.19% | -3.36 | -89.17% | 0.00% | 0.00% | 4.97% | -2.99 | -3.71 | 19.46 | 0.53 |
| BCRX | BioCryst Pharmaceuticals,… | $8.75 | 1.84B | +993% | +143,402% | -35% | +1,311% | 6.86 | -15.20 | 2.07 | 4.45 | — | -15.20 | 97.82% | 38.98% | 30.16% | -88.68% | -199.20% | 52.53% | -0.10 | 4.32 | 2.06 | 1.40 | -0.22 | -38140.00% | 9410.00% | -75364.00% | 19.18% | 1.77 | -205.64% | 0.00% | 0.00% | 44.97% | 4.54 | 4.46 | 1.77 | 1.99 |
| BHVN | Biohaven Ltd. | $11.52 | 1.22B | — | — | — | — | -3.22 | 6.43 | — | -2.59 | -5.20 | 6.75 | 0.00% | — | — | -198.83% | -3466.81% | -150.03% | 0.09 | — | 3.49 | 3.17 | 0.07 | 6195.00% | — | 7519.00% | -21.53% | -3.78 | -2297.22% | 0.00% | 0.00% | 0.00% | -2.57 | -3.88 | — | 1.47 |
| IMNM | Immunome, Inc. | $21.86 | 2B | +132% | -83% | — | +492% | -1.87 | 3.02 | 60.58 | -2.21 | — | 3.02 | 100.00% | -3382.37% | -3240.38% | -194.63% | 1276.40% | -150.71% | 0.03 | — | 4.08 | 4.00 | 0.92 | -706.00% | -3550.00% | 185621.00% | -30.00% | -2.04 | 685.79% | 0.00% | 0.00% | 7.58% | -1.10 | -2.04 | 37.08 | -0.77 |
| PHVS | Pharvaris N.V. | $28.39 | 1.84B | — | — | — | — | -5.23 | 2.59 | — | -2.84 | — | 2.59 | 0.00% | — | — | -40.62% | 1529.52% | -38.37% | 0.00 | — | 12.60 | 12.35 | 1.92 | -570.00% | — | 2956.00% | -17.42% | -5.23 | 1266.85% | 0.00% | 0.00% | 0.00% | -2.83 | -3.42 | — | 15.12 |
| STOK | Stoke Therapeutics, Inc. | $36.41 | 2.08B | +35% | +5,275% | — | — | -4.86 | 1.89 | 11.83 | -2.20 | — | 1.89 | 100.00% | -277.31% | -243.42% | -45.80% | 800.63% | -35.60% | 0.01 | — | 5.81 | 5.43 | 1.27 | -3067.00% | 31634.00% | 529.00% | -20.12% | -2.17 | 687.55% | 0.00% | 0.00% | 0.00% | -2.15 | -2.50 | 5.96 | 3.33 |
| SYRE | Spyre Therapeutics, Inc. | $43.01 | 2.6B | — | — | — | — | -94.74 | 20.56 | — | -66.55 | — | 20.56 | 0.00% | — | — | -25.17% | 331.08% | -22.39% | 0.00 | — | 13.25 | 12.89 | 0.41 | -3774.00% | — | 752.00% | -1.15% | -2.88 | 267.42% | 0.00% | 0.00% | 0.00% | -66.55 | -82.40 | — | 139.24 |
| UPB | Upstream Bio, Inc. | $7.68 | 415.02M | +226% | +2% | -60% | — | -7.31 | 0.98 | 193.67 | 0.12 | -17.44 | 0.98 | 100.00% | -3281.18% | -2650.04% | -36.23% | 67.14% | -20.97% | 0.00 | — | 44.63 | 43.93 | 4.17 | 4190.00% | -42.00% | 5677.00% | -13.00% | -5.51 | 51.53% | 0.00% | 0.00% | 64.98% | 0.12 | 0.16 | -4.06 | 23.29 |
| WVE | Wave Life Sciences Ltd. | $13.93 | 2.59B | +134% | -54% | — | +334% | -11.43 | 4.51 | 54.67 | -8.57 | -15.69 | 4.51 | 0.00% | -504.09% | -478.33% | -56.16% | 323.63% | -108.74% | 0.03 | — | 6.47 | 6.35 | 2.86 | 7286.00% | -6055.00% | 2338.00% | -8.03% | -1.97 | 281.72% | 0.00% | 0.00% | 13.17% | -8.13 | -9.34 | 40.99 | 1.20 |
| ZBIO | Zenas BioPharma, Inc. | $26.35 | 1.1B | -12% | -81% | — | +1,012% | -1.98 | 1.00 | 62.26 | 0.23 | -0.69 | 1.00 | -2682.78% | -3277.76% | -3139.76% | -361.99% | 109.71% | -71.66% | 0.00 | — | 6.21 | 6.12 | 1.95 | 28763.00% | -9000.00% | 29221.00% | -38.49% | -2.09 | 80.20% | 0.00% | 0.00% | 90.91% | 0.23 | 0.32 | -7.69 | 1.30 |
| ZYME | Zymeworks Inc. | $23.29 | 1.74B | +9% | -79% | — | — | -7.42 | 2.69 | 11.93 | -6.47 | — | 2.83 | 100.00% | -179.69% | -160.80% | -30.54% | -110.26% | -23.51% | 0.05 | — | 3.40 | 3.19 | 0.44 | -581.00% | 38.00% | -757.00% | -12.43% | -1.25 | -90.96% | 0.00% | 0.00% | 3.30% | -5.13 | -6.21 | 9.21 | 1.62 |
About Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
- CEO
- John Leonard
- Employees
- 403
- Beta
- 2.11
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($6.97 ÷ $13.26) − 1 = -47.44% (DCF, example).